Modifications and Substitutions of the RNA Extraction Module in the ViroSeq™ HIV-1 Genotyping System Version 2: Effects on Sensitivity and Complexity of the Assay

Journal of Medical Virology

Volumn 71, Issue 4, 2003, Pages 475-479

  Stürmer, Martin ^a,b   Berger, Annemarie ^a   Doerr, Hans Wilhelm ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Amplification success rate; Cut off; Genotypic assay; RNA extraction

Indexed keywords

VIRUS RNA;

ARTICLE; ELUTION; GENE AMPLIFICATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LABORATORY DIAGNOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; RNA EXTRACTION; ULTRACENTRIFUGATION; VIRUS LOAD; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0142182292     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10527     Document Type: Article

References (21)

1. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. 2002. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16:1039-1044.
2. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14:F83-F93.
3. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A. 2002. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 16:369-379.
4. Cunningham S, Ank B, Lewis D, Lu W, Wantman M, Dileanis JA, Jackson JB, Palumbo P, Krogstad P, Eshleman SH. 2001. Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol 39:1254-1257.
5. d'Arminio MA, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M. 1998. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 12:1631-1637.
6. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. 1999. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
7. Elbeik T, Hoo BS, Campodonico ME, Dileanis J, Fay FF, Bortolozzi RL, Benetti MS, Fay OH, Marlowe N, Petrauskene O, Chernoff D, Smith L, Ng VL. 2001. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J Hum Virol 4:317-328.
8. Erali M, Page S, Reimer LG, Hillyard DR. 2001. Human immunodeficiency virus type 1 drug resistance testing: A comparison of three sequence-based methods. J Clin Microbiol 39:2157-2165.
9. Gallego O, Ruiz L, Vallejo A, Clotet B, Leal M, Soriano V. 2002. Rate of Virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol 40:3865-3866.
10. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society - USA Panel. JAMA 283:2417-2426.
11. Larder BA, Kemp SD. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
12. Larder BA, Darby G, Richman DD. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
13. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860.
14. Panel on Clinical Practices for Treatment of HIV. 2002. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Morb Mortal Wkly Rep 51:1-55.
15. Ross L, Vavro CL, Kehne SL, McClernon DR, St. Clair M. 2001. Substitution of a commercially available, RNA extraction procedure in an HIV-1 genotyping system improves sensitivity and allows reduced sample volume. J Virol Methods 96:1-4.
16. Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, Segondy M. 2001. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 26:36-43.
17. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, Benders I, Boucher CA. 2002. Underestimation of HIV type 1 drug resistance mutations: Results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 18:243-248.
18. The EuroGuidelines Group for HIV Resistance. 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. The EuroGuidelines Group for HIV Resistance. AIDS 15:309-320.
19. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B. 2002. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 16:209-218.
20. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. 1999. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 20:290-294.
21. Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, Lange JM. 1999. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 179:790-798.